AptaBio Therapeutics Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-29,378	-12,062	-10,565
Depreciation & Amortization	531.35	539.11	484.62
Loss (Gain) From Sale of Investments	583.55	244.29	2,494
Loss (Gain) on Equity Investments	583.5	4.19	-
Stock-Based Compensation	234.34	186.65	123.6
Other Operating Activities	12,478	-2,458	631.31
Change in Accounts Receivable	-893.71	-	-
Change in Inventory	-224.87	-	-
Change in Accounts Payable	1.87	-	-
Change in Other Net Operating Assets	3,924	-549.77	-1.91
Operating Cash Flow	-12,160	-14,095	-6,833
Capital Expenditures	-240.16	-1,345	-1,041
Sale (Purchase) of Intangibles	-	-46.6	-10.36
Investment in Securities	13,521	-9,006	5,332
Other Investing Activities	-55.62	60.15	27.66
Investing Cash Flow	12,854	-12,737	1,743
Long-Term Debt Issued	-	38,900	-
Long-Term Debt Repaid	-134.01	-127.85	-87.95
Net Debt Issued (Repaid)	-134.01	38,772	-87.95
Issuance of Common Stock	-	-	589.2
Other Financing Activities	-33.3	-19.2	-5.24
Financing Cash Flow	-167.31	49,854	496.01
Foreign Exchange Rate Adjustments	-1.19	5.07	16.76
Miscellaneous Cash Flow Adjustments	-0	-0	0
Net Cash Flow	525.33	23,027	-4,577
Free Cash Flow	-12,400	-15,440	-7,874
Free Cash Flow Margin	-368.94%	-4767.39%	-16284.04%
Free Cash Flow Per Share	-526.76	-681.01	-353.27
Cash Interest Paid	10.2	11.47	4.49
Cash Income Tax Paid	76.18	48.45	-34.01
Levered Free Cash Flow	-1,924	-13,398	-
Unlevered Free Cash Flow	201.3	-12,659	-
Change in Net Working Capital	-12,623	1,429	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.